Kezdőlap・Részvénylista・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Lezárt

34.01 -0.5

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

33.31

Maximum

34.04

Fő mutatók
By Trading Economics
Bevétel	43M 13M
Értékesítés	29M 107M
Egy részvényre jutó nyereség	0.25
Profit margin	12.139
Munkavállalók	524
EBITDA	25M 17M

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+92.35% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	200M 1.6B
Előző nyitás	34.51
Előző zárás	34.01

Immunocore Holdings PLC ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 7. 20:04 UTC

News

Immunocore Holdings reported a wider Q2 loss of 2 cents per share and $115.9 million in revenue, with shares trading lower since Thursday's close.

2026. aug. 6. 19:52 UTC

News

Immunocore Holdings PLC reported Q2 earnings of -$0.02 per share and revenue of $115.93 million, exceeding expectations. Shares are trading higher during Thursday's session.

2026. aug. 5. 20:02 UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

2026. aug. 4. 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

2026. aug. 3. 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

2026. júl. 31. 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

2026. júl. 28. 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

2026. júl. 27. 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

2026. júl. 24. 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

2026. júl. 22. 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

2026. júl. 21. 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

2026. júl. 20. 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Társak összehasonlítása

Árváltozás

Immunocore Holdings PLC ADR Előrejelzés

Célár

By TipRanks

92.35% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 65.4 USD 92.35%

Magas 100 USD

Alacsony 35 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Immunocore Holdings PLC ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

5 ratings

Vétel

Tartás

Eladás

5 Wall Street elemző célárain alapulva a(z)Immunocore Holdings PLC ADR termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.